1. CHIATAI TIANQING TQH3906 Treatment of PlaquePhase II Clinical Data of Psoriasis Shines
Independently developed by CHIATAI TIANQING 1 Innovative Drug Class TQH3906（TYK2/JAK1JH2 Allosteric Inhibitor）Phase II Clinical Trial for Moderate to Severe Plaque Psoriasis Meets Primary Endpoint. At the Recommended Dose Treatment12 At the same time,PASI 75 Response rate exceeds 90% ，PASI 90 Response rate exceeds 70% `, and all dose groups were safe`The overall safety profile was good, with an incidence of adverse reactions comparable to that of the placebo group.TQH3906 By targeting the pseudokinase domain (JH2）Achieving high selectivity, it is expected to provide a new option for oral small molecule targeted therapy for psoriasis patients. The study enrolled209 For example, patients, and the results will be announced at an international academic conference.
2. Hansoh Pharma and Hengrui Pharma Reach 1.9 Yi Yuan AuthorizationCooperation
Hengrui Pharma SHR6508 Project (Novel Calcium-Sensing Receptor Allosteric Modulators) in Mainland ChinaThe exclusive rights for development, production, and commercialization have been granted to Hansoh Pharma.Medicine.SHR6508 Intended for the treatment of chronic kidneySecondary Hyperparathyroidism in Patients with Heart Disease, CurrentlyPhase III clinical stage. Hansoh Pharma paid the initialPayment 3000 Ten thousand yuan, and may pay up to 1.9 Regulatory and commercial milestone payments in the hundreds of millions, as well as salesCommission (Maximum9%). This related party transaction is based on the trust relationship between the two parties.System, aimed at reducing transaction costs and acceleratingProject Promotion.
3. China Biopharmaceuticals NewCo Mode Entry"Submit the Test Paper" "Stage"
2025 Year, represented by Hengrui Pharma, Kang Nuoya Biomedical Technology (Chengdu) Co., Ltd., and GenSci.Table of Chinese pharmaceutical companies passed NewCo Model (SeaEstablishing new companies abroad and authorizing core assets to achieve rapid capitalization and globalization. Typical cases include: Hengrui Pharma andKailera（GLP-1/GIP Dual-target drug) and Braveheart(Myosin Inhibitor) Collaboration;GenSci Assets Approved Yarrow Reverse Merger VYNE Achieve 48 Within hours of the U.S. stock market listing; Kang Nuoya Biomedical Technology (Chengdu) Co., Ltd.Over Belenos And Timberlyne Spin-off Pipeline Financing. This model leverages the valuation differences between the US and China, enhancing innovation in China.The global competitiveness of new drugs depends on geopolitical stability and capital efficiency.
4. U.S. Media Evaluates China's Technological Progress in Resisting U.S. Suppression
Bloomberg reported that, despite 2025 Year United States CustomsTax Policy Leads to a Decline in China's Exports to the U.S. 29%, but China has offset the losses by expanding exports to markets in Europe, Latin America, and others. In the technology field, China is making strides in renewableEnergy (such as electric vehicles, batteries, solar panels) occupies a global leading position, the United States65%Grid-scale lithiumIon batteries rely on supplies from China. Meanwhile, China is rapidly catching up in the fields of self-developed AI chips and quantum computing, Nobel laureate John ·Martinez said the technology gap between China and the US has narrowed to “Nanosecond-level ”。
5. Huadong Medicine GLP-1/GIP Dual-Target Product Submission for Pet Drug Market Launch
PrabotulinumtoxinA Injection developed by Sinopharm Zhongmei Huadong, a wholly-owned subsidiary of Huadong Medicine (GLP-1/GIP Dual-target stimulationNew Veterinary Drug Application for Dopaminergic Agents Accepted by the Ministry of Agriculture and Rural Affairs, Indicated for weight management in obese adult cats. Phase III clinical trial results show that weekly dosing 6 Weeks later, the obese cat's weight decreased relative to the baseline. 9.26%, exceeding 70%Animal body weight decreased significantly 5% . The product was well tolerated, and noRelated to adverse reactions, it is expected to become a petImportant Innovative Drug in the Field of Weight Loss.
6.The Lancet Publishes New Advances in Alzheimer's Disease Diagnosis
The Lancet Special Issue Systematically Expounds on Alzheimer's Disease (AD) DiagnosisBreakthroughs in Diagnosis, Treatment, and Prevention.Regulatory blood biomarkers (such asβ-Amyloid andtau The application of protein will revolutionize clinical diagnostic processes.Improve the Accuracy of Early Screening. Global AD Patient about 3200 Ten thousand, mild recognitionPatients with cognitive impairment 6900 Wan. WenChapter ProposedA-T-N Model Revision: Differentiating Populations Based on Genetic and Biomarker ProfilesCognitive trajectory, and promoteRecommended Primary Healthcare Targeted Cognitive Screening Tools (e.g.,MoCA) and the stratified diagnostic pathway for memory clinics.
7. First Release of the Commercial Health Insurance Innovative Drug List
The National Healthcare Security Administration Releases the First Edition of the "Innovative Drug List for Commercial Health Insurance," Covering 19 InnovativeMedicines, covering areas such as oncology, rare diseases, and chronic diseases, including 5 Made in China CAR-T Therapies and Two Alzheimer'sAlzheimer's Disease Drugs (Leqembi, Lecanemab). Directory Highlight"Basic medical insurance, commercialFrontier Preservation "Positioning, alleviating the payment pressure of high-value drugs through a dynamic linkage mechanism. The policy clarifies the commercial insurance catalog."Drugs not included DRG/DIP Assessment, to encourage hospital use. This move aims to integrate social capital and enhance innovation.New Drug Accessibility.
The reference materials are from publicly available online information, including news, corporate official websites, and government documents.
